{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Recurrent or progressive malignancy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Acute graft-versus-host disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Chronic GVHD with bronchiolitis obliterans"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Multiorgan failure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Diffuse alveolar hemorrhage"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemolytic uremic syndrome"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Medical condition that made the greatest contribution in causing death","groups":[{"description":"Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treated Patients"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to 6 years after enrollment","title":"Causes of Death","type":"SECONDARY","unitOfMeasure":"Participants"}